Although we acknowledge the potential applicability of CISH in ascertaining HER2 gene amplification in breast cancer patients who are candidates for trastuzumab therapy, the scoring system proposed for EGFR FISH in NSCLC currently cannot be extrapolated to CISH technology. The gene discussed is ERBB2; the disease is breast cancer.